Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children
Whangbo et al.
Blood Advances
September 2019
Authors and Affiliates
Whangbo JS1,2,3, Kim HT4,5, Mirkovic N6, Leonard L1,2, Poryanda S6, Silverstein S1,2, Kim S6, Reynolds CG6, Rai SC6, Verrill K1,2, Lee MA1,2,3, Margossian S1,2,3, Duncan C1,2,3, Lehmann L1,2,3, Huang J3,7, Nikiforow S3,6, Alyea EP 3rd3,6, Armand P3,6, Cutler CS3,6, Ho VT3,6, Blazar BR8, Antin JH3,6, Soiffer RJ3,6, Ritz J3,6, Koreth J3,6.;
1
Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
2
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston MA.
3
Harvard Medical School, Boston, MA.
4
Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA.
5
Harvard School of Public Health, Boston, MA.
6
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
7
Dermatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA; and.
8
Masonic Cancer Center and Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.